Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Roxana Dronca MD
Roxana S. Dronca MD Advisory Board
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · February 25, 2016

Apatinib in Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or GEJ

Journal of Clinical Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Journal of Clinical Oncology
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
J. Clin. Oncol 2016 Feb 16;[EPub Ahead of Print], J Li, S Qin, J Xu, J Xiong, C Wu, Y Bai, W Liu, J Tong, Y Liu, R Xu, Z Wang, Q Wang, X Ouyang, Y Yang, Y Ba, J Liang, X Lin, D Luo, R Zheng, X Wang, G Sun, L Wang, L Zheng, H Guo, J Wu, N Xu, J Yang, H Zhang, Y Cheng, N Wang, L Chen, Z Fan, P Sun, H Yu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated